OXFORD, England, July 6, 2010 /PRNewswire/ -- Elsevier, the world-leading publisher of scientific, technical and medical information products and services, and the International Society of Geriatric Oncology (SIOG) announced today the launch of the Journal of Geriatric Oncology (http://www.geriatriconcology.net). The journal is focused on advancing research in the pathogenesis, biology, treatment, and survivorship issues of older adults with cancer. It covers all aspects of geriatric oncology, from basic scientific research through to clinical research, as well as research that is relevant to education and policy development.
Older adults represent the majority of individuals with cancer, and the number of older individuals with cancer is growing as our society ages and life expectancy increases. Despite such a compelling need for geriatric oncology research, it has been challenging to disseminate this research into mainstream geriatric or oncology journals, said Dr Arti Hurria, Editor-in-Chief of the Journal of Geriatric Oncology.
Matti Aapro, Executive Director of SIOG and Founding Editor of the Journal of Geriatric Oncology noted, It is imperative that chronologic age alone does not prevent senior adult patients from receiving treatment and care for their cancer, which is in line with best practice. To achieve this goal, there was clearly a need for a journal specialized in geriatric oncology. Thus, Elsevier and the International Society for Geriatric Oncology decided that it was time to launch the Journal of Geriatric Oncology, which should become the leading source of updated information in this complex area.
The Editorial Board is led by Editor-in-Chief, Arti Hurria, and Founding Editor, Matti Aapro. Dr Hurria is a geriatrician and oncologist, focusing on care of the older patient with cancer. She completed a geriatric fellowship in the Harvard Geriatric Fellowship Program, followed by a hematology-oncology fellowship at Memorial Sloan-Kettering Cancer Center (MSKCC). Dr Hurria subsequently joined the faculty at MSKCC, and in 2006 joined the City of Hope as Director of the Cancer and Aging Research Program. Dr. Hurria is a cadre member of the Cancer and Leukemia Group B, Cancer in the Elderly Committee and is a recipient of the Paul Beeson Career Development Award in Aging Research (K23 AG026749-01) and American Society of Clinical Oncology-Association of Specialty Professors-Junior Development Award in Geriatric Oncology.
Dr Aapro is Dean of the Multidisciplinary Oncology Institute at the Clinique de Genolier in Genolier, Switzerland. In addition to his role as Executive Director of SIOG, Dr. Aapro is also an active member of several professional organizations. He is a Board member and past-President of the Multinational Association for Supportive Care in Cancer (MASCC) and a member and past-Chair of the Cancer in the Elderly Task Force of the European Organization for Research and Treatment of Cancer (EORTC).
About the Journal of Geriatric Oncology
The Journal of Geriatric Oncology is an international, multidisciplinary journal which is focused on advancing research in the pathogenesis, biology, treatment, and survivorship issues of older adults with cancer. The journal covers all aspects of geriatric oncology, from basic scientific research through to clinical research, as well as research that is relevant to education and policy development.
The Journal of Geriatric Oncology publishes original research articles, review articles, clinical trials, treatment guidelines, education and training articles, editorials, short communications, perspectives, meeting reports and letters to the editor which comment on previously published work. The Journal of Geriatric Oncology is the official journal of the International Society of Geriatric Oncology (SIOG).
About the International Society of Geriatric Oncology (SIOG)
The International Society of Geriatric Oncology, or Societe Internationale d'Oncologie Geriatrique in French (SIOG), was founded in 2000. The major risk factor for cancer is age, and with the aging of the world population, a major epidemiologic challenge is before us.
The goal of SIOG is to foster the development of health professionals in the field of geriatric oncology, in order to optimize treatment of older adults with cancer. It promotes efforts in training, research, policy and care to support this mission. SIOG is a multidisciplinary society, including physicians in the fields of oncology and geriatrics, and allied health professionals. Its annual conference is the leading conference for experts in the field to interact and share their results.
It has members in more than 40 countries around the world. SIOG honors a prominent world expert in the field each year with the Calabresi Award, named after its first president: Dr Paul Calabresi, past-President of the American Society for Clinical Oncology (ASCO), whose vision contributed greatly to the development of geriatric oncology.
For more information: http://www.siog.org
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet (http://www.thelancet.com) and Cell (http://www.cell.com ), and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect (http://www.sciencedirect.com), Scopus (http://www.scopus.com), Reaxys (http://www.reaxys.com), MD Consult (http://www.mdconsult.com) and Nursing Consult (http://www.nursingconsult.com), which enhance the productivity of science and health professionals, and the SciVal suite (http://www.scival.com ) and MEDai's Pinpoint Review (http://www.medai.com), which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier ( http://www.elsevier.com) employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC (http://www.reedelsevier.com), a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Sarah Jenkins Publisher, Global Medical Research +44-1865-843243 email@example.com
CONTACT: Sarah Jenkins, Publisher, Global Medical Research,+44-1865-843243, firstname.lastname@example.org